Magazine on Mastitis and Milk quality for the dairy professional
Boehringer Ingelheim continues to stay at the forefront of innovation and provide producers with the right tools for disease prevention. The Company’s Ubroseal® Blue brings confidence of best practice when it comes to sealant administration and removal
Read MoreUbrolexin®, a combination of kanamycin and cefalexin has been marketed for the intramammary treatment of clinical mastitis in lactating dairy cows in 27 countries by Boehringer-Ingelheim since 2008. The combination broadens the spectrum of activity attributed to either agent alone, and synergy between the two agents has been demonstrated forRead more
Read MoreTwenty-three countries were represented at the 59th National Mastitis Council (NMC) Annual Meeting, held January 28-31 (2020), in Orlando, Florida, USA. International attendees accounted for 31 percent of the attendees.
Read MoreWhen I arrived at the University of Minnesota in 1998 as a newly minted assistant professor, I had then only just begun to dabble in mastitis research. This content is for M²-DIGITAL, M²-PREMIUM, M²-INSTITUTIONAL & NMC members only. Log in if you have a valid subscription and continue your readingRead more
Read MoreMilk quality has evolved over the last several decades from a focus on control of contagious pathogens through improvements in milking technique and blanket dry cow treatment addressing the challenges of environmental mastitis. This can be attributed in large part to the National Mastitis Council and the 5-point plan. We’veRead more
Read More
